Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a research report sent to investors on Saturday morning.

Several other equities analysts also recently issued reports on the stock. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Cantor Fitzgerald boosted their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $62.83.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $47.64 on Friday. The stock has a market capitalization of $2.77 billion, a P/E ratio of -24.81, a P/E/G ratio of 0.78 and a beta of 0.56. The company’s fifty day moving average price is $46.17 and its 200 day moving average price is $48.93. Supernus Pharmaceuticals has a 1 year low of $40.26 and a 1 year high of $59.68.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. grew its stake in Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 660 shares in the last quarter. Torren Management LLC purchased a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $49,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $51,000. Hantz Financial Services Inc. increased its holdings in shares of Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 458 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $55,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.